Zoetis Inc. (ZTS) 주식 분석

회사 개요

Zoetis Inc. is a prominent entity within the healthcare sector, specifically operating in the drug manufacturing industry focused on specialty and generic pharmaceuticals for the animal health sector. The company engages in the comprehensive lifecycle of animal health solutions, including the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, services, biodevices, genetic tests, and precision animal health solutions for markets in the United States and internationally. Zoetis operates at a significant scale with a total market capitalization of $52.77 billion, annual revenue of $9.47 billion, and an employee base comprising 14,500 individuals. These financial metrics and operational scale indicate that the company holds a substantial position in the global animal health landscape, reflecting a robust revenue generation capability and a large workforce dedicated to specialized pharmaceutical research and distribution.

재무 건전성

The company reported a total revenue of $9.47 billion and generated a net income of $2.67 billion, with an EBITDA of $4.07 billion over the trailing twelve months. The gap between the $9.47 billion revenue and the $2.67 billion net income reveals a highly efficient cost structure, where operating expenses and taxes consume approximately 71.8% of gross revenue before reaching the bottom line. Zoetis demonstrated strong cash generation capabilities with a free cash flow of $1.79 billion, which provides the entity with considerable financial flexibility to fund research initiatives, acquire smaller competitors, or return capital to shareholders without needing to raise external equity. The company maintains a gross margin of 71.9%, an operating margin of 34.7%, and a profit margin of 28.2%, all of which indicate pricing power in a specialized market where high-value veterinary products command premium valuations. On the balance sheet, Zoetis holds $2.31 billion in cash against $9.31 billion in debt, resulting in a debt-to-equity ratio of 279.59, which suggests a leveraged capital structure typical for capital-intensive pharmaceutical manufacturers that utilize debt to finance growth. However, the current ratio stands at 3.03, indicating that the company possesses more than three times the current assets required to cover its short-term liabilities, signaling robust short-term liquidity and an ability to meet obligations comfortably. Furthermore, the return on equity is an impressive 66.0% while the return on assets is 15.3%, metrics that collectively reveal highly effective management in deploying capital to generate superior returns compared to industry peers.

밸류에이션 평가

Zoetis currently trades with a trailing twelve-month P/E ratio of 19.89 and a forward P/E of 15.87. The notable difference between the trailing P/E and the forward P/E implies that the market expects earnings to grow significantly in the coming year, thereby compressing the valuation multiple as investors anticipate higher profitability relative to the current stock price. The price-to-book ratio is 15.28, which indicates that the market values the company at a substantial premium over its tangible book value, reflecting the high intangible assets associated with intellectual property and brand equity in the pharmaceutical industry. Additional valuation metrics include a price-to-sales ratio of 5.57 and an EV/EBITDA of 14.15, figures that suggest the market is willing to pay a high multiple for sales and earnings due to the company's dominant market position and consistent cash flow generation. The stock has a 52-week high of $172.23 and a 52-week low of $113.29, providing a range within which the current trading price fluctuates based on market sentiment and earnings expectations. The beta value of 0.97 indicates that the stock price volatility is closely aligned with the broader market, moving slightly less aggressively than the general market index during periods of fluctuation.

Growth & Income

Zoetis is currently experiencing a revenue growth rate of 3.0% and an earnings growth rate of 6.1% year-over-year. The fact that earnings are growing faster than revenue at 6.1% compared to 3.0% implies that the company is benefiting from favorable pricing dynamics, cost efficiencies, or a shift in product mix that enhances profitability without a proportional increase in top-line sales volume. As a dividend payer, Zoetis offers a dividend yield of 1.8% with a payout ratio of 33.2%, a figure that suggests the dividend is highly sustainable given that less than one-third of earnings are distributed while the remainder is retained for reinvestment. This payout ratio is particularly prudent in the pharmaceutical sector, ensuring that the company maintains sufficient earnings reserves to cover the $9.31 billion in debt and fund ongoing R&D pipelines. Overall, the growth and income profile of Zoetis reflects a balanced approach where modest revenue expansion supports accelerating earnings per share growth while maintaining a conservative and sustainable dividend policy for long-term income investors.